[ad_1]
Glenmark Pharmaceuticals It said on Saturday that its consolidated profit after tax declined 26 per cent to Rs 173 crore for the fourth quarter ended March 31, 2022. The company had reported profit after tax (PAT) of Rs 234 crore in the January-March period of 2020-21 financials.
However, the pharmaceutical firm’s consolidated revenue rose to Rs 3,019 crore in the quarter under review from Rs 2,860 crore in the year-ago period, registering a year-on-year growth of 6 per cent. For the year ended March 31, 2022, the Mumbai-based pharmaceutical firm reported a PAT of Rs 994 crore as against Rs 970 crore in FY2011.
The company’s consolidated revenue for the last financial year increased to Rs 12,305 crore from Rs 10,944 crore in 2020-21. “We delivered consistent performance throughout the year and achieved our key objectives despite the challenging global macro environment,” Glenmark Pharmaceuticals Chairman and Managing Director Glen Saldanha said in a statement.
He said the company was successful in listing Glenmark Lifesciences on the Indian stock exchanges and the out-licensing deal for ISB 880 along with USFDA approval for Almirol and Rialtris has cemented the pharmaceutical firm as a leading innovation-driven pharma company in the country. established.
“We are confident of growing our business with a continued emphasis on prioritizing free cash generation over innovation, sustainability and additional debt reduction,” Saldanha said.
The company said that its board has recommended a dividend of Rs 2.5 per share on the face value of Rs 2.5 each for the financial year 2021-22
[ad_2]
Source link
